CA
NZ
UK
AU
IND
US
● Veracyte reported second-quarter 2026 totalRevenueof $150.3 million, up 15% year over year, withGAAPNet Incomeof $25.5 million, and raised full-year revenue guidance to $596 million.
● Syndax Pharmaceuticals grew second-quarter 2026 netRevenuefrom its two approved drugs, with Revuforj up 91% year over year to $54.7 million and Niktimvo up 67% to $60.3 million.
● Savara faces an FDA PDUFA action date of November 22, 2026 for MOLBREEVI in autoimmune pulmonary alveolar proteinosis, backed by $173.0 million in cash and up to $150 million in non-dilutive funding available upon approval.
● Ultragenyx faces an FDA PDUFA action date of 19 September 2026 for UX111 gene therapy in Sanfilippo syndrome, after Phase 3 misses in both its setrusumab and GTX-102 programs.
● Incyte reported second-quarter 2026 totalRevenueof about $1.67 billion, up 38% year over year, withGAAPNet Incomeof about $585.6 million, and raised full-year 2026 net-sales guidance to roughly $5.13 billion to $5.26 billion.
● GeneDx Holdings reported Q2 2026Revenueof roughly $114.4 million, up sequentially, with its net loss narrowing to about $17.7 million.
● Sensus Healthcare reported Q2 2026Revenueof about $2.3 million with a loss per share of roughly $0.53, citing delayed financing approvals for eight units.
● ICU Medical reported Q2 2026Revenueof about $551.7 million and raised full-year adjusted EBITDA guidance to $415 million-$435 million.
● CRISPR Therapeutics reported Q2 2026Revenueof about $10.18 million and held roughly $2.36 billion in cash, while presenting new cardiovascular pipeline data in August 2026.
● Kiniksa Pharmaceuticals reported second-quarter 2026Revenueof $243.6 million, up roughly 55% year over year, and raised full-year 2026 ARCALYST guidance to $995 million from a prior $945 million.
Please wait processing your request...